Professor Shihui Wei, Leader of the Neuro-Ophthalmology Group of the Ophthalmology Branch of the Chinese Medical Association, Visits Neurophth Biology for Guidance

Neurophth’s New Brand, New Standard, and New Achievement Highlighted at World Health Expo

Neurophth Announces Completion of Patient Enrollment in U.S. Phase I/II Clinical Trial for Nurofex® (Opvika)

Neurophth and Sinopharm Holding Collaborate to Successfully Complete the Winter Transportation Verification of Newvision®, Pioneering the Commercial Transportation and Storage of AAV Gene Therapy in China

Five-year Follow-up of Argentine Patients with LHON-ND4 Treated with NFS-01 (NR082, Trade Name: Newvision®)

Neurophth Awarded as "Optics Valley Rising Star" of Deloitte China in 2023

Special interview with Chinese and international top neuro-ophthalmologists on LHON Awareness Day

Neurophth Secures Australian Approval for Ophthalmic Gene Therapy

Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy